Aus­tralian bio­phar­ma buys ra­dioiso­tope pro­duc­er in its next step to ‘dou­ble’ ca­pac­i­ty in 2024 

Telix Phar­ma­ceu­ti­cals is still on its ra­dio­phar­ma man­u­fac­tur­ing shop­ping spree. The Aus­tralian biotech is buy­ing com­mer­cial-stage ra­dioiso­tope pro­duc­er ARTMS for $57.5 mil­lion up­front, with an ex­tra $24.5 mil­lion for fu­ture mile­stones.

Just last week, Telix al­so an­nounced it bought Texas-based ra­dio­phar­ma com­pa­ny IsoTher­a­peu­tics for $8 mil­lion up­front. For 2023, Telix tout­ed it dou­bled its in-house man­u­fac­tur­ing, with plans to dou­ble again in 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER